SLC5A2 and heart failure: In summary, the multifaceted therapeutic potential of SGLT2 inhibitors—including the prevention of chemotherapy-related cardiotoxicity, restoration of cardiac function in heart failure, and possible anticancer properties—positions these agents as promising candidates within the evolving field of cardio-oncology.